Anti-VEGF agents

PreclinicalSmall molecule

SSt. Olavs Hospital

Anti-VEGF agents is one of 4 small molecule programs targeting Intravitreal Injections. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intravitreal InjectionsCompleted

NeovascularNot yet recruiting

Intravitreal InjectionsPreclinical

Completed

NeovascularPreclinical

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Intravitreal Injections

#DrugCompanyPhaseTrials

IRX-101

IiRenix Medical, Inc.

Phase 3

1 2

Ophthaine

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 3

Anti-VEGF agents

SSt. Olavs Hospital

Preclinical

1 4

Optive

IInnovative Medical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalNot yet recruiting

Neovascular

NCT07744204

Clinical

Trials by Indication[1]

Intravitreal Injections1 trial

Intravitreal Injections by Nurses and Physicians Compared

Completed·SSt. Olavs Hospital·N/A·NCT02359149·328 enrolled

Neovascular1 trial

Laser-Enhanced Anti-VEGF Precise Penetration (LEAP) Strategy for Neovascular Age-Related Macular Degeneration: A Multicentre, Prospective, Stratified Block-Randomised Controlled Trial

Not yet recruiting·CChinese PLA General Hospital·Preclinical·NCT07744204·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-VEGF agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-VEGF agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-VEGF agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Olavs Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSt. Olavs Hospital

Anti-VEGF agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Intravitreal Injections1 trial

Neovascular1 trial

References

Drug Info

Quick Facts

Related News